SIMILAR PATTERNS OF AMINO ACIDS FOR 3G0F_B_B49B9001

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 416 ALA A 428 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.64A	3g0fB-1k2pA: 27.2	3g0fB-1k2pA: 34.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 209 ALA A 220 THR A 266 TYR A 268 GLY A 272 LEU A 321	None	0.61A	3g0fB-1k9aA: 30.4	3g0fB-1k9aA: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 267 VAL A 275 ALA A 288 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.33A	3g0fB-1opkA: 30.5	3g0fB-1opkA: 26.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 VAL A 624 ALA A 642 TYR A 693 CYH A 694 GLY A 697 LEU A 818 CYH A 828	None	0.48A	3g0fB-1rjbA: 38.8	3g0fB-1rjbA: 56.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 78 VAL A 86 ALA A 99 GLY A 153 LEU A 201 CYH A 211	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 4.7A) ATP A 535 (-4.8A) ATP A 535 ( 4.5A)	0.63A	3g0fB-1s9iA: 12.2	3g0fB-1s9iA: 25.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 595 VAL A 603 ALA A 621 THR A 670 TYR A 672 CYH A 673 GLY A 676 LEU A 799 CYH A 809 PHE A 811	STI A 3 ( 3.8A) STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-3.2A) STI A 3 ( 4.0A) STI A 3 (-4.5A) STI A 3 ( 3.8A) STI A 3 (-4.4A) STI A 3 (-4.5A) STI A 3 (-3.6A)	0.63A	3g0fB-1t46A: 41.6	3g0fB-1t46A: 92.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u5q	SERINE/THREONINE PROTEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	6	VAL A 42 ALA A 55 TYR A 107 CYH A 108 GLY A 110 LEU A 158	None	0.48A	3g0fB-1u5qA: 23.8	3g0fB-1u5qA: 26.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 15 VAL A 23 ALA A 36 TYR A 86 CYH A 87 GLY A 90 LEU A 137	HYM A 400 (-4.2A) HYM A 400 (-4.3A) HYM A 400 (-3.5A) HYM A 400 (-4.7A) HYM A 400 (-4.2A) None HYM A 400 (-4.5A)	0.34A	3g0fB-1zltA: 13.1	3g0fB-1zltA: 27.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU X 17 VAL X 25 ALA X 37 THR X 82 TYR X 84 GLY X 88 LEU X 137	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-4.1A) STU X 902 (-4.6A) STU X 902 (-3.5A) STU X 902 (-4.4A)	0.40A	3g0fB-2dq7X: 30.8	3g0fB-2dq7X: 35.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2gcd	SERINE/THREONINE-PRO TEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	6	VAL A 42 ALA A 55 TYR A 107 CYH A 108 GLY A 110 LEU A 158	STU A 400 ( 4.8A) STU A 400 (-3.2A) STU A 400 (-4.5A) STU A 400 (-4.0A) STU A 400 (-3.4A) STU A 400 ( 4.6A)	0.46A	3g0fB-2gcdA: 24.9	3g0fB-2gcdA: 26.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 273 VAL A 281 ALA A 293 THR A 338 TYR A 340 GLY A 344 LEU A 393	H8H A 534 (-3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.2A) H8H A 534 (-3.1A) H8H A 534 (-4.3A) H8H A 534 (-3.3A) H8H A 534 (-4.5A)	0.62A	3g0fB-2h8hA: 28.5	3g0fB-2h8hA: 22.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hw6	MAP KINASE-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 55 VAL A 63 ALA A 76 GLY A 130 LEU A 177 CYH A 190	None	0.57A	3g0fB-2hw6A: 20.4	3g0fB-2hw6A: 23.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 248 VAL A 256 ALA A 269 THR A 315 GLY A 321 LEU A 370	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.4A) None GIN A 600 (-4.7A)	0.49A	3g0fB-2hz0A: 31.8	3g0fB-2hz0A: 33.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 251 VAL A 259 ALA A 271 THR A 316 TYR A 318 GLY A 322 PHE A 383	None None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.7A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A)	1.14A	3g0fB-2og8A: 30.3	3g0fB-2og8A: 34.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 259 ALA A 271 THR A 316 TYR A 318 GLY A 322 LEU A 371 PHE A 383	None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.7A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A) 1N8 A 501 ( 4.3A)	1.07A	3g0fB-2og8A: 30.3	3g0fB-2og8A: 34.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 588 VAL A 596 ALA A 614 THR A 663 TYR A 665 CYH A 666 GLY A 669 LEU A 785	None	0.42A	3g0fB-2ogvA: 38.2	3g0fB-2ogvA: 67.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 487 VAL A 495 ALA A 515 TYR A 566 GLY A 570 LEU A 633	None	0.36A	3g0fB-2psqA: 33.8	3g0fB-2psqA: 44.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	VAL A 689 ALA A 705 THR A 753 TYR A 755 GLY A 759 LEU A 807	None	0.70A	3g0fB-2r2pA: 31.2	3g0fB-2r2pA: 32.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 724 VAL A 732 ALA A 749 THR A 796 GLY A 802 LEU A 850	GW7 A 1 ( 4.2A) GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-4.0A) GW7 A 1 (-3.6A) GW7 A 1 (-4.2A)	0.80A	3g0fB-2r4bA: 28.0	3g0fB-2r4bA: 30.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2wtk	SERINE/THREONINE-PRO TEIN KINASE 11 (Homo sapiens)	PF00069 (Pkinase)	6	LEU C 55 VAL C 63 ALA C 76 TYR C 131 CYH C 132 LEU C 183	ANP C 2 ( 4.4A) ANP C 2 (-4.2A) ANP C 2 (-3.4A) None ANP C 2 (-4.5A) None	0.60A	3g0fB-2wtkC: 21.8	3g0fB-2wtkC: 24.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	6	VAL A 635 ALA A 651 THR A 699 TYR A 701 GLY A 705 LEU A 753	Q9G A1898 ( 4.7A) Q9G A1898 (-3.2A) Q9G A1898 (-3.5A) Q9G A1898 (-4.8A) Q9G A1898 ( 3.8A) Q9G A1898 (-4.3A)	0.75A	3g0fB-2xyuA: 31.6	3g0fB-2xyuA: 31.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 487 VAL A 495 ALA A 515 TYR A 566 GLY A 570 LEU A 633	M33 A1996 (-4.0A) M33 A1996 ( 4.7A) M33 A1996 (-3.3A) M33 A1996 ( 4.7A) M33 A1996 ( 4.8A) M33 A1996 (-4.5A)	0.34A	3g0fB-3b2tA: 33.1	3g0fB-3b2tA: 47.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 484 VAL A 492 ALA A 512 TYR A 563 GLY A 567 LEU A 630 PHE A 489	C4F A 1 ( 3.9A) None C4F A 1 (-3.3A) None None C4F A 1 (-4.6A) C4F A 1 (-3.7A)	0.75A	3g0fB-3c4fA: 32.8	3g0fB-3c4fA: 46.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 209 ALA A 220 THR A 266 TYR A 268 GLY A 272 LEU A 321	None	0.61A	3g0fB-3d7uA: 30.8	3g0fB-3d7uA: 32.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 833 VAL A 841 ALA A 859 CYH A 912 GLY A 915 LEU A1029 CYH A1039 PHE A1041	8ST A2001 ( 4.7A) 8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 (-3.8A) None None 8ST A2001 (-4.2A) 8ST A2001 ( 3.7A)	0.73A	3g0fB-3hngA: 40.0	3g0fB-3hngA: 45.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 833 VAL A 841 ALA A 859 TYR A 911 CYH A 912 GLY A 915 LEU A1029 CYH A1039	8ST A2001 ( 4.7A) 8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 (-4.9A) 8ST A2001 (-3.8A) None None 8ST A2001 (-4.2A)	0.58A	3g0fB-3hngA: 40.0	3g0fB-3hngA: 45.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kex	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 696 VAL A 704 THR A 768 TYR A 770 GLY A 774 LEU A 822	ANP A 1 (-4.4A) ANP A 1 (-3.9A) ANP A 1 ( 4.8A) ANP A 1 (-4.3A) ANP A 1 ( 4.9A) ANP A 1 (-4.7A)	0.63A	3g0fB-3kexA: 26.7	3g0fB-3kexA: 28.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lm5	SERINE/THREONINE-PRO TEIN KINASE 17B (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 39 VAL A 47 ALA A 60 TYR A 112 GLY A 116 LEU A 165	QUE A 1 ( 3.8A) QUE A 1 ( 4.6A) QUE A 1 (-3.2A) QUE A 1 (-4.9A) None None	0.47A	3g0fB-3lm5A: 23.5	3g0fB-3lm5A: 24.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	6	VAL A 218 ALA A 229 THR A 279 TYR A 281 GLY A 285 LEU A 339	LDN A 1 ( 4.8A) LDN A 1 (-3.6A) LDN A 1 (-3.8A) LDN A 1 ( 4.8A) LDN A 1 (-3.3A) LDN A 1 (-4.5A)	0.53A	3g0fB-3mdyA: 23.9	3g0fB-3mdyA: 27.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mvj	CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 49 VAL A 57 ALA A 70 TYR A 122 GLY A 126 LEU A 173	XFE A 351 (-4.2A) XFE A 351 ( 4.5A) XFE A 351 (-3.2A) None None XFE A 351 (-4.6A)	0.37A	3g0fB-3mvjA: 21.8	3g0fB-3mvjA: 23.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 88 VAL A 96 ALA A 109 TYR A 161 GLY A 165 LEU A 212	JOZ A 361 (-4.1A) JOZ A 361 ( 4.7A) JOZ A 361 (-3.4A) None None None	0.42A	3g0fB-3nuuA: 23.3	3g0fB-3nuuA: 24.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 726 VAL A 734 ALA A 751 THR A 798 GLY A 804 LEU A 852	03Q A 1 (-3.8A) 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.1A) 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A)	0.80A	3g0fB-3pp0A: 28.6	3g0fB-3pp0A: 29.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	7	VAL A 565 ALA A 576 THR A 625 TYR A 627 GLY A 631 LEU A 683 CYH A 693	STU A 1 (-4.9A) STU A 1 (-3.3A) STU A 1 (-4.1A) STU A 1 (-4.4A) STU A 1 (-3.2A) STU A 1 (-4.3A) STU A 1 (-3.5A)	0.69A	3g0fB-3ppzA: 27.5	3g0fB-3ppzA: 33.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q5i	PROTEIN KINASE (Plasmodium berghei)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	LEU A 63 VAL A 71 ALA A 84 THR A 144 GLY A 150 LEU A 197	ANP A1634 ( 4.3A) ANP A1634 (-4.1A) ANP A1634 (-3.6A) ANP A1634 (-4.6A) None ANP A1634 (-4.4A)	0.41A	3g0fB-3q5iA: 20.1	3g0fB-3q5iA: 20.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 423 VAL A 431 ALA A 443 THR A 489 TYR A 491 GLY A 495 LEU A 543	PP2 A 1 (-4.1A) PP2 A 1 (-4.5A) PP2 A 1 (-3.2A) PP2 A 1 (-3.3A) PP2 A 1 ( 4.9A) PP2 A 1 ( 4.2A) PP2 A 1 (-4.6A)	0.66A	3g0fB-3sxsA: 29.9	3g0fB-3sxsA: 34.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 484 VAL A 492 ALA A 512 TYR A 563 GLY A 567 LEU A 630	07J A 1 ( 4.3A) 07J A 1 (-4.0A) 07J A 1 (-3.5A) 07J A 1 (-4.7A) 07J A 1 (-3.7A) 07J A 1 ( 4.4A)	0.40A	3g0fB-3tt0A: 33.5	3g0fB-3tt0A: 42.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ulz	BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	LEU A 295 VAL A 303 ALA A 315 TYR A 365 GLY A 369 LEU A 423	None	0.80A	3g0fB-3ulzA: 21.9	3g0fB-3ulzA: 24.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 544 VAL A 552 ALA A 570 TYR A 619 GLY A 623 LEU A 686	0F4 A 902 ( 4.2A) None 0F4 A 902 (-3.2A) 0F4 A 902 (-4.2A) 0F4 A 902 (-3.4A) 0F4 A 902 (-4.5A)	0.54A	3g0fB-3v5qA: 32.7	3g0fB-3v5qA: 34.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 840 VAL A 848 ALA A 866 CYH A 919 GLY A 922 LEU A1035 CYH A1045	4TT A2001 ( 4.0A) 4TT A2001 ( 4.5A) 4TT A2001 (-3.5A) 4TT A2001 (-4.3A) 4TT A2001 (-3.7A) 4TT A2001 (-4.8A) None	0.63A	3g0fB-3vidA: 34.9	3g0fB-3vidA: 46.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3w18	AURORA KINASE A (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 139 VAL A 147 ALA A 160 TYR A 212 GLY A 216 LEU A 263	N13 A 501 (-3.7A) N13 A 501 ( 4.7A) N13 A 501 ( 4.1A) N13 A 501 (-4.4A) N13 A 501 (-3.5A) N13 A 501 (-4.5A)	0.20A	3g0fB-3w18A: 22.1	3g0fB-3w18A: 24.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 840 VAL A 848 ALA A 866 CYH A 919 GLY A 922 LEU A1035 CYH A1045	LEV A1201 ( 3.8A) LEV A1201 ( 4.9A) LEV A1201 (-3.5A) LEV A1201 (-4.1A) LEV A1201 (-3.6A) LEV A1201 (-4.8A) GOL A1210 ( 3.3A)	0.66A	3g0fB-3wzdA: 34.2	3g0fB-3wzdA: 52.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4af3	AURORA KINASE B (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 83 VAL A 91 ALA A 104 TYR A 156 GLY A 160 LEU A 207	VX6 A 500 (-3.8A) VX6 A 500 ( 4.8A) VX6 A 500 (-3.4A) VX6 A 500 (-4.2A) VX6 A 500 (-3.3A) VX6 A 500 (-4.6A)	0.44A	3g0fB-4af3A: 19.7	3g0fB-4af3A: 27.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 840 VAL A 848 ALA A 866 CYH A 919 GLY A 922 LEU A1035 CYH A1045 PHE A1047	B49 A2000 (-3.7A) None B49 A2000 (-3.5A) B49 A2000 (-4.2A) B49 A2000 ( 3.7A) B49 A2000 (-4.5A) B49 A2000 ( 4.1A) B49 A2000 (-4.0A)	0.63A	3g0fB-4agdA: 39.8	3g0fB-4agdA: 50.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 18 ALA A 31 TYR A 82 CYH A 83 LEU A 133 CYH A 143	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 (-4.8A) D15 A 500 (-4.3A) D15 A 500 (-4.5A) D15 A 500 ( 4.0A)	0.62A	3g0fB-4aguA: 23.0	3g0fB-4aguA: 24.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 560 VAL A 568 ALA A 586 TYR A 635 GLY A 639 LEU A 699	LTI A1839 ( 4.2A) None LTI A1839 (-3.3A) LTI A1839 (-4.7A) LTI A1839 (-3.4A) LTI A1839 (-4.2A)	0.64A	3g0fB-4at3A: 31.5	3g0fB-4at3A: 32.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 42 VAL A 50 ALA A 63 CYH A 113 GLY A 116 LEU A 164	XZN A1317 (-3.6A) XZN A1317 ( 4.7A) XZN A1317 (-3.5A) XZN A1317 (-3.7A) XZN A1317 ( 3.7A) XZN A1317 (-4.7A)	0.75A	3g0fB-4bc6A: 21.2	3g0fB-4bc6A: 28.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	6	VAL A 222 ALA A 233 THR A 283 TYR A 285 GLY A 289 LEU A 343	TAK A1507 (-4.7A) TAK A1507 (-3.3A) TAK A1507 (-3.6A) TAK A1507 ( 4.6A) TAK A1507 (-3.5A) TAK A1507 (-4.7A)	0.82A	3g0fB-4c02A: 24.7	3g0fB-4c02A: 25.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c0t	LIKELY PROTEIN KINASE (Candida albicans)	PF00069 (Pkinase)	6	LEU A 246 VAL A 254 ALA A 267 TYR A 320 GLY A 324 LEU A 371	None	0.46A	3g0fB-4c0tA: 22.9	3g0fB-4c0tA: 16.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4cfh	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1 (Rattus norvegicus)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	6	LEU A 22 VAL A 30 ALA A 43 TYR A 95 GLY A 99 LEU A 146	STU A1550 (-4.3A) None STU A1550 (-3.1A) STU A1550 (-4.5A) STU A1550 (-3.4A) STU A1550 (-4.3A)	0.55A	3g0fB-4cfhA: 22.9	3g0fB-4cfhA: 20.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 653 THR A 701 TYR A 703 GLY A 707 LEU A 773 PHE A 785	DI1 A1000 (-3.6A) DI1 A1000 (-3.6A) DI1 A1000 (-4.0A) None DI1 A1000 (-4.5A) DI1 A1000 (-4.5A)	0.81A	3g0fB-4ckrA: 32.8	3g0fB-4ckrA: 31.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 663 VAL A 671 ALA A 684 TYR A 739 GLY A 743 LEU A 789	AGS A1985 (-4.2A) AGS A1985 (-4.6A) AGS A1985 (-3.5A) None None AGS A1985 (-4.8A)	0.38A	3g0fB-4crsA: 14.0	3g0fB-4crsA: 22.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f0i	HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 515 VAL A 523 ALA A 541 TYR A 590 GLY A 594 LEU A 656	None	0.74A	3g0fB-4f0iA: 32.6	3g0fB-4f0iA: 35.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	6	LEU A 855 VAL A 863 ALA A 880 TYR A 931 GLY A 935 LEU A 983	IZA A2001 (-3.7A) None IZA A2001 (-3.4A) None IZA A2001 (-3.3A) IZA A2001 ( 4.7A)	0.68A	3g0fB-4gl9A: 28.1	3g0fB-4gl9A: 32.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 828 VAL A 836 ALA A 853 TYR A 904 GLY A 908 LEU A 956	19S A1201 (-3.9A) 19S A1201 (-4.4A) 19S A1201 (-3.3A) 19S A1201 (-4.7A) 19S A1201 ( 3.8A) 19S A1201 (-4.5A)	0.39A	3g0fB-4hviA: 29.3	3g0fB-4hviA: 31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	6	LEU A 132 VAL A 140 ALA A 156 THR A 205 GLY A 211 LEU A 259	None	0.57A	3g0fB-4hzsA: 27.1	3g0fB-4hzsA: 32.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 132 VAL A 140 ALA A 156 THR A 205 GLY A 211 LEU A 259	1G0 A 401 ( 4.5A) 1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 (-3.2A) 1G0 A 401 ( 4.5A) 1G0 A 401 (-4.6A)	0.56A	3g0fB-4id7A: 13.4	3g0fB-4id7A: 34.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jxf	SERINE/THREONINE-PRO TEIN KINASE PLK4 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 18 VAL A 26 ALA A 39 CYH A 92 GLY A 95 LEU A 143	631 A 301 (-3.4A) 631 A 301 (-4.6A) 631 A 301 (-3.3A) 631 A 301 (-4.5A) 631 A 301 ( 3.7A) 631 A 301 (-4.0A)	0.42A	3g0fB-4jxfA: 18.4	3g0fB-4jxfA: 25.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 273 VAL A 281 ALA A 293 TYR A 340 GLY A 344 LEU A 393	0J9 A 601 (-4.0A) 0J9 A 601 (-4.4A) 0J9 A 601 (-3.3A) 0J9 A 601 ( 4.7A) 0J9 A 601 ( 4.1A) 0J9 A 601 (-4.5A)	0.71A	3g0fB-4k11A: 28.1	3g0fB-4k11A: 26.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 478 VAL A 486 ALA A 506 TYR A 557 GLY A 561 LEU A 624	ACP A 801 (-3.8A) ACP A 801 (-4.2A) ACP A 801 (-3.3A) None ACP A 801 ( 4.6A) ACP A 801 (-4.4A)	0.62A	3g0fB-4k33A: 27.3	3g0fB-4k33A: 47.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4l52	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7, TGF-BETA-ACTIVATED KINASE 1 AND MAP3K7-BINDING PROTEIN 1 CHIMERA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 50 ALA A 61 TYR A 106 GLY A 110 LEU A 163 CYH A 174	1UL A 501 ( 4.9A) 1UL A 501 (-3.1A) 1UL A 501 (-4.1A) 1UL A 501 ( 3.7A) 1UL A 501 (-4.3A) 1UL A 501 (-3.6A)	0.66A	3g0fB-4l52A: 25.2	3g0fB-4l52A: 28.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lg4	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 33 VAL A 41 ALA A 54 TYR A 101 CYH A 102 GLY A 105	GOL A 404 ( 3.6A) GOL A 404 (-4.5A) GOL A 404 ( 3.1A) GOL A 404 ( 4.9A) GOL A 403 (-4.0A) GOL A 404 (-3.6A)	0.51A	3g0fB-4lg4A: 23.5	3g0fB-4lg4A: 26.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lg4	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 41 ALA A 54 TYR A 101 CYH A 102 GLY A 105 LEU A 153	GOL A 404 (-4.5A) GOL A 404 ( 3.1A) GOL A 404 ( 4.9A) GOL A 403 (-4.0A) GOL A 404 (-3.6A) GOL A 403 ( 4.4A)	0.66A	3g0fB-4lg4A: 23.5	3g0fB-4lg4A: 26.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	LEU A 273 VAL A 281 ALA A 293 TYR A 340 GLY A 344 LEU A 393	VGG A 601 (-3.2A) VGG A 601 ( 3.5A) VGG A 601 (-3.5A) VGG A 601 ( 4.0A) VGG A 601 ( 3.2A) VGG A 601 (-4.5A)	0.75A	3g0fB-4lggA: 27.6	3g0fB-4lggA: 35.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mvf	CALCIUM-DEPENDENT PROTEIN KINASE 2 (Plasmodium falciparum)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	LEU A 78 VAL A 86 ALA A 99 CYH A 149 GLY A 151 LEU A 199	STU A 601 ( 4.0A) STU A 601 (-4.8A) STU A 601 (-3.3A) STU A 601 (-4.2A) STU A 601 (-3.4A) STU A 601 (-4.7A)	0.53A	3g0fB-4mvfA: 18.9	3g0fB-4mvfA: 21.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 46 VAL A 54 ALA A 67 THR A 123 CYH A 126 GLY A 128 LEU A 180 CYH A 190	SIN A 401 ( 3.9A) None SIN A 401 ( 3.7A) None SIN A 401 (-4.3A) SIN A 401 (-3.5A) SIN A 401 ( 4.5A) None	0.61A	3g0fB-4o38A: 20.2	3g0fB-4o38A: 24.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 595 VAL A 603 THR A 687 TYR A 689 GLY A 693 LEU A 741	2TT A1201 (-4.1A) 2TT A1201 (-4.2A) None 2TT A1201 (-4.0A) 2TT A1201 (-3.5A) 2TT A1201 (-4.1A)	0.82A	3g0fB-4oliA: 27.0	3g0fB-4oliA: 22.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 903 VAL A 911 ALA A 928 TYR A 980 GLY A 984 LEU A1030	2TT A1202 (-3.5A) 2TT A1202 (-4.5A) 2TT A1202 ( 3.9A) 2TT A1202 (-4.6A) 2TT A1202 (-3.4A) 2TT A1202 (-4.4A)	0.48A	3g0fB-4oliA: 27.0	3g0fB-4oliA: 22.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 627 VAL A 635 ALA A 648 TYR A 703 GLY A 707 LEU A 753	None	0.32A	3g0fB-4otdA: 22.2	3g0fB-4otdA: 23.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2k	EPHRIN TYPE-A RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	VAL A 627 ALA A 644 THR A 692 TYR A 694 GLY A 698 LEU A 746	None	0.81A	3g0fB-4p2kA: 30.6	3g0fB-4p2kA: 32.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4q9z	HUMAN PROTEIN KINASE C THETA (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 386 VAL A 394 ALA A 407 TYR A 460 GLY A 464 LEU A 511	PZW A 801 (-3.9A) PZW A 801 (-4.6A) PZW A 801 (-3.5A) None None PZW A 801 (-4.8A)	0.69A	3g0fB-4q9zA: 20.5	3g0fB-4q9zA: 24.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rew	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1 (Homo sapiens)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	6	LEU A 24 VAL A 32 ALA A 45 TYR A 97 GLY A 101 LEU A 148	STU A 601 (-3.7A) STU A 601 ( 4.8A) STU A 601 (-3.2A) STU A 601 (-4.4A) STU A 601 ( 3.8A) STU A 601 (-4.2A)	0.54A	3g0fB-4rewA: 22.4	3g0fB-4rewA: 19.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 616 VAL A 624 ALA A 642 TYR A 693 CYH A 694 GLY A 697 LEU A 818 CYH A 828 PHE A 830	P30 A1001 (-3.8A) None P30 A1001 (-3.4A) P30 A1001 (-4.1A) None P30 A1001 (-3.4A) P30 A1001 (-4.6A) P30 A1001 (-4.1A) P30 A1001 (-3.9A)	0.61A	3g0fB-4rt7A: 40.7	3g0fB-4rt7A: 48.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	7	LEU A 14 VAL A 22 ALA A 35 THR A 81 TYR A 83 GLY A 87 LEU A 136	ACP A1264 ( 4.5A) ACP A1264 (-4.7A) ACP A1264 (-2.9A) ACP A1264 (-4.5A) ACP A1264 ( 4.5A) ACP A1264 (-3.5A) ACP A1264 ( 4.8A)	0.67A	3g0fB-4ueuA: 31.0	3g0fB-4ueuA: 35.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wb7	DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase) PF00226 (DnaJ)	6	LEU A 104 VAL A 112 ALA A 125 TYR A 177 GLY A 181 LEU A 228	ATP A 501 ( 4.3A) ATP A 501 (-4.0A) ATP A 501 (-3.4A) None None ATP A 501 (-4.5A)	0.39A	3g0fB-4wb7A: 21.5	3g0fB-4wb7A: 23.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wov	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 595 VAL A 603 THR A 687 TYR A 689 GLY A 693 LEU A 741	3SM A 901 (-3.9A) 3SM A 901 ( 4.4A) 3SM A 901 ( 4.6A) 3SM A 901 (-3.2A) 3SM A 901 (-3.0A) 3SM A 901 (-4.1A)	0.69A	3g0fB-4wovA: 22.5	3g0fB-4wovA: 25.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 52 VAL A 60 ALA A 72 CYH A 129 GLY A 132 LEU A 183 CYH A 193	KSA A 405 ( 4.0A) KSA A 405 ( 4.9A) KSA A 405 (-3.2A) KSA A 405 (-4.5A) KSA A 405 (-3.5A) KSA A 405 (-4.6A) KSA A 405 (-3.4A)	0.54A	3g0fB-4wsqA: 22.6	3g0fB-4wsqA: 22.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	6	LEU B 267 VAL B 275 ALA B 288 THR B 334 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.71A	3g0fB-4xeyB: 30.6	3g0fB-4xeyB: 30.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 408 VAL A 416 ALA A 428 THR A 474 TYR A 476 LEU A 528	None	0.77A	3g0fB-4xi2A: 28.6	3g0fB-4xi2A: 26.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 616 VAL A 624 ALA A 642 TYR A 693 CYH A 694 GLY A 697 LEU A 818 CYH A 828 PHE A 830	P30 A1001 (-4.0A) P30 A1001 ( 4.8A) P30 A1001 (-3.5A) P30 A1001 ( 4.4A) P30 A1001 (-4.2A) P30 A1001 (-3.5A) P30 A1001 (-4.3A) P30 A1001 (-4.8A) P30 A1001 ( 4.1A)	0.70A	3g0fB-4xufA: 39.9	3g0fB-4xufA: 60.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	7	LEU A 408 VAL A 416 ALA A 428 THR A 474 TYR A 476 GLY A 480 LEU A 528	746 A 702 (-3.8A) 746 A 702 ( 4.3A) 746 A 702 (-2.4A) 746 A 702 (-3.7A) 746 A 702 (-4.4A) 746 A 702 (-3.6A) 746 A 702 (-4.4A)	0.54A	3g0fB-4y93A: 29.7	3g0fB-4y93A: 26.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 477 ALA A 488 THR A 539 TYR A 541 GLY A 545 LEU A 595	None 4CV A 801 (-3.5A) 4CV A 801 (-2.8A) 4CV A 801 (-3.9A) 4CV A 801 ( 4.0A) 4CV A 801 (-4.4A)	0.56A	3g0fB-4yffA: 24.8	3g0fB-4yffA: 28.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ysj	CALMODULIN-LIKE DOMAIN PROTEIN KINASE (Eimeria tenella)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	LEU A 34 VAL A 42 ALA A 55 THR A 105 GLY A 111 LEU A 158	ADP A 506 ( 3.8A) ADP A 506 (-4.3A) ADP A 506 (-3.3A) ADP A 506 ( 4.6A) None ADP A 506 (-4.7A)	0.44A	3g0fB-4ysjA: 22.5	3g0fB-4ysjA: 19.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 484 VAL A 492 ALA A 512 TYR A 563 GLY A 567 LEU A 630	38O A1769 (-3.2A) 38O A1769 (-4.5A) 38O A1769 (-3.6A) 38O A1769 (-4.2A) 38O A1769 (-3.4A) 38O A1769 (-4.6A)	0.29A	3g0fB-5a46A: 33.8	3g0fB-5a46A: 41.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ci7	SERINE/THREONINE-PRO TEIN KINASE ULK1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 30 ALA A 44 TYR A 94 CYH A 95 GLY A 98 LEU A 145	51W A 401 ( 4.3A) 51W A 401 (-3.4A) 51W A 401 ( 3.4A) 51W A 401 (-3.9A) 51W A 401 (-3.7A) 51W A 401 (-4.5A)	0.28A	3g0fB-5ci7A: 23.4	3g0fB-5ci7A: 29.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5e8y	TGF-BETA RECEPTOR TYPE-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 258 ALA A 275 THR A 325 GLY A 331 LEU A 386 CYH A 396	STU A 601 (-4.0A) STU A 601 (-3.1A) STU A 601 ( 3.7A) STU A 601 (-3.5A) STU A 601 (-3.9A) STU A 601 (-3.2A)	0.61A	3g0fB-5e8yA: 24.2	3g0fB-5e8yA: 27.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 903 VAL A 911 ALA A 928 TYR A 980 GLY A 984 LEU A1030	5U3 A1200 (-3.8A) 5U3 A1200 ( 4.4A) 5U3 A1200 (-3.5A) 5U3 A1200 (-4.5A) 5U3 A1200 (-3.2A) 5U3 A1200 (-4.4A)	0.37A	3g0fB-5f1zA: 22.2	3g0fB-5f1zA: 32.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 730 VAL A 738 ALA A 756 TYR A 806 GLY A 810 LEU A 881	PP1 A2012 (-4.6A) PP1 A2012 (-4.4A) PP1 A2012 (-3.2A) None PTR A 809 (-2.4A) PP1 A2012 (-4.6A)	0.66A	3g0fB-5fm2A: 32.0	3g0fB-5fm2A: 42.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 599 VAL A 607 ALA A 625 THR A 674 TYR A 676 CYH A 677 GLY A 680 LEU A 825 CYH A 835 PHE A 837	748 A1001 (-3.8A) 748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-3.2A) 748 A1001 (-4.0A) 748 A1001 (-4.5A) 748 A1001 ( 4.0A) 748 A1001 (-4.3A) 748 A1001 (-4.5A) 748 A1001 (-3.7A)	0.61A	3g0fB-5grnA: 30.8	3g0fB-5grnA: 60.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5gz8	PROTEIN O-MANNOSE KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	6	VAL A 94 ALA A 105 THR A 148 TYR A 150 GLY A 154 LEU A 215	None	0.62A	3g0fB-5gz8A: 18.4	3g0fB-5gz8A: 22.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5gza	PROTEIN O-MANNOSE KINASE (Danio rerio)	PF07714 (Pkinase_Tyr)	6	VAL A 93 ALA A 104 THR A 147 TYR A 149 GLY A 153 LEU A 214	ADP A 401 (-4.4A) ADP A 401 (-3.2A) ADP A 401 ( 4.8A) ADP A 401 ( 4.8A) ADP A 401 ( 4.1A) ADP A 401 (-4.4A)	0.65A	3g0fB-5gzaA: 18.2	3g0fB-5gzaA: 23.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hes	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 30 ALA A 43 THR A 82 TYR A 84 GLY A 88 CYH A 150	032 A 401 (-4.4A) 032 A 401 (-3.2A) 032 A 401 (-3.7A) 032 A 401 (-4.2A) 032 A 401 ( 4.0A) 032 A 401 (-3.6A)	0.78A	3g0fB-5hesA: 24.6	3g0fB-5hesA: 26.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 57 VAL A 65 ALA A 77 TYR A 132 CYH A 133 GLY A 136 LEU A 187 CYH A 197	IDV A 401 (-3.8A) IDV A 401 (-4.6A) IDV A 401 (-3.6A) IDV A 401 (-3.5A) IDV A 401 (-4.6A) IDV A 401 (-3.4A) IDV A 401 (-4.4A) IDV A 401 (-3.6A)	0.69A	3g0fB-5i3oA: 22.4	3g0fB-5i3oA: 25.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5iso	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2 (Homo sapiens)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	6	LEU A 22 VAL A 30 ALA A 43 TYR A 95 GLY A 99 LEU A 146	STU A 601 (-4.1A) STU A 601 (-4.8A) STU A 601 (-3.3A) STU A 601 (-4.3A) STU A 601 ( 4.0A) STU A 601 (-4.5A)	0.40A	3g0fB-5isoA: 22.8	3g0fB-5isoA: 19.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5o0y	SERINE/THREONINE-PRO TEIN KINASE TOUSLED-LIKE 2 (Homo sapiens)	no annotation	6	LEU A 468 VAL A 476 ALA A 489 TYR A 546 CYH A 547 GLY A 549	AGS A 801 (-4.1A) AGS A 801 (-4.0A) AGS A 801 (-3.6A) AGS A 801 ( 4.8A) AGS A 801 (-4.3A) None	0.66A	3g0fB-5o0yA: 21.2	3g0fB-5o0yA: 12.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5tvt	MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (Homo sapiens)	no annotation	6	VAL A 25 ALA A 38 TYR A 88 CYH A 89 GLY A 92 LEU A 139	7LV A 401 ( 4.6A) 7LV A 401 (-3.4A) 7LV A 401 (-4.6A) 7LV A 401 (-4.3A) None 7LV A 401 (-4.9A)	0.43A	3g0fB-5tvtA: 22.4	3g0fB-5tvtA: 23.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	7	LEU A 24 VAL A 32 ALA A 45 THR A 95 TYR A 97 GLY A 101 LEU A 153	9WS A 401 ( 4.2A) 9WS A 401 ( 4.6A) 9WS A 401 (-3.3A) 9WS A 401 (-3.2A) None 9WS A 401 ( 4.3A) 9WS A 401 (-4.6A)	0.54A	3g0fB-5w5jA: 8.9	3g0fB-5w5jA: 28.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	7	LEU A 891 VAL A 899 ALA A 917 THR A 963 TYR A 965 GLY A 969 LEU A1017	ANP A1201 (-4.1A) ANP A1201 (-4.4A) ANP A1201 (-3.3A) ANP A1201 (-3.9A) ANP A1201 (-4.4A) ANP A1201 ( 4.6A) ANP A1201 (-4.7A)	0.71A	3g0fB-5wnoA: 26.0	3g0fB-5wnoA: 11.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	7	LEU A 33 VAL A 41 ALA A 54 TYR A 101 CYH A 102 GLY A 105 LEU A 153	ANP A 501 ( 3.8A) ANP A 501 (-4.4A) ANP A 501 ( 3.7A) ANP A 501 ( 4.2A) ANP A 501 (-4.2A) ANP A 501 ( 4.0A) ANP A 501 (-4.6A)	0.64A	3g0fB-6ao5A: 21.5	3g0fB-6ao5A: 23.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fdy	- (-)	no annotation	6	LEU U 20 VAL U 28 ALA U 42 CYH U 94 GLY U 97 LEU U 144	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 (-4.2A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A)	0.73A	3g0fB-6fdyU: 21.9	3g0fB-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fek	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	no annotation	6	LEU A 730 VAL A 738 ALA A 756 TYR A 806 GLY A 810 LEU A 881	ADN A1104 ( 4.0A) ADN A1104 (-4.4A) ADN A1104 (-3.4A) ADN A1104 ( 4.1A) ADN A1104 ( 3.8A) ADN A1104 (-4.3A)	0.58A	3g0fB-6fekA: 31.8	3g0fB-6fekA: 19.23

[["3G0F_B_B49B9001_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",6,"VAL A 416;ALA A 428;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.64A","3g0fB-1k2pA:27.2","3g0fB-1k2pA:34.87"],["3G0F_B_B49B9001_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 209;ALA A 220;THR A 266;TYR A 268;GLY A 272;LEU A 321","None","0.61A","3g0fB-1k9aA:30.4","3g0fB-1k9aA:28.57"],["3G0F_B_B49B9001_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 267;VAL A 275;ALA A 288;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.33A","3g0fB-1opkA:30.5","3g0fB-1opkA:26.33"],["3G0F_B_B49B9001_1","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A 616;VAL A 624;ALA A 642;TYR A 693;CYH A 694;GLY A 697;LEU A 818;CYH A 828","None","0.48A","3g0fB-1rjbA:38.8","3g0fB-1rjbA:56.48"],["3G0F_B_B49B9001_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",6,"LEU A  78;VAL A  86;ALA A  99;GLY A 153;LEU A 201;CYH A 211","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 4.7A);ATP A 535 (-4.8A);ATP A 535 ( 4.5A)","0.63A","3g0fB-1s9iA:12.2","3g0fB-1s9iA:25.42"],["3G0F_B_B49B9001_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",10,"LEU A 595;VAL A 603;ALA A 621;THR A 670;TYR A 672;CYH A 673;GLY A 676;LEU A 799;CYH A 809;PHE A 811","STI A   3 ( 3.8A);STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-3.2A);STI A   3 ( 4.0A);STI A   3 (-4.5A);STI A   3 ( 3.8A);STI A   3 (-4.4A);STI A   3 (-4.5A);STI A   3 (-3.6A)","0.63A","3g0fB-1t46A:41.6","3g0fB-1t46A:92.86"],["3G0F_B_B49B9001_1","1u5q","Rattus norvegicus","SERINE\/THREONINE PROTEIN KINASE TAO2","PF00069(Pkinase)",6,"VAL A  42;ALA A  55;TYR A 107;CYH A 108;GLY A 110;LEU A 158","None","0.48A","3g0fB-1u5qA:23.8","3g0fB-1u5qA:26.32"],["3G0F_B_B49B9001_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",7,"LEU A  15;VAL A  23;ALA A  36;TYR A  86;CYH A  87;GLY A  90;LEU A 137","HYM A 400 (-4.2A);HYM A 400 (-4.3A);HYM A 400 (-3.5A);HYM A 400 (-4.7A);HYM A 400 (-4.2A);None;HYM A 400 (-4.5A)","0.34A","3g0fB-1zltA:13.1","3g0fB-1zltA:27.09"],["3G0F_B_B49B9001_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",7,"LEU X  17;VAL X  25;ALA X  37;THR X  82;TYR X  84;GLY X  88;LEU X 137","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-4.1A);STU X 902 (-4.6A);STU X 902 (-3.5A);STU X 902 (-4.4A)","0.40A","3g0fB-2dq7X:30.8","3g0fB-2dq7X:35.61"],["3G0F_B_B49B9001_1","2gcd","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE TAO2","PF00069(Pkinase)",6,"VAL A  42;ALA A  55;TYR A 107;CYH A 108;GLY A 110;LEU A 158","STU A 400 ( 4.8A);STU A 400 (-3.2A);STU A 400 (-4.5A);STU A 400 (-4.0A);STU A 400 (-3.4A);STU A 400 ( 4.6A)","0.46A","3g0fB-2gcdA:24.9","3g0fB-2gcdA:26.98"],["3G0F_B_B49B9001_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 273;VAL A 281;ALA A 293;THR A 338;TYR A 340;GLY A 344;LEU A 393","H8H A 534 (-3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.2A);H8H A 534 (-3.1A);H8H A 534 (-4.3A);H8H A 534 (-3.3A);H8H A 534 (-4.5A)","0.62A","3g0fB-2h8hA:28.5","3g0fB-2h8hA:22.91"],["3G0F_B_B49B9001_1","2hw6","Homo sapiens","MAP KINASE-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 1","PF00069(Pkinase)",6,"LEU A  55;VAL A  63;ALA A  76;GLY A 130;LEU A 177;CYH A 190","None","0.57A","3g0fB-2hw6A:20.4","3g0fB-2hw6A:23.58"],["3G0F_B_B49B9001_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",6,"LEU A 248;VAL A 256;ALA A 269;THR A 315;GLY A 321;LEU A 370","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.4A);None;GIN A 600 (-4.7A)","0.49A","3g0fB-2hz0A:31.8","3g0fB-2hz0A:33.63"],["3G0F_B_B49B9001_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",7,"LEU A 251;VAL A 259;ALA A 271;THR A 316;TYR A 318;GLY A 322;PHE A 383","None;None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.7A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A)","1.14A","3g0fB-2og8A:30.3","3g0fB-2og8A:34.51"],["3G0F_B_B49B9001_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",7,"VAL A 259;ALA A 271;THR A 316;TYR A 318;GLY A 322;LEU A 371;PHE A 383","None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.7A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A);1N8 A 501 ( 4.3A)","1.07A","3g0fB-2og8A:30.3","3g0fB-2og8A:34.51"],["3G0F_B_B49B9001_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",8,"LEU A 588;VAL A 596;ALA A 614;THR A 663;TYR A 665;CYH A 666;GLY A 669;LEU A 785","None","0.42A","3g0fB-2ogvA:38.2","3g0fB-2ogvA:67.38"],["3G0F_B_B49B9001_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"LEU A 487;VAL A 495;ALA A 515;TYR A 566;GLY A 570;LEU A 633","None","0.36A","3g0fB-2psqA:33.8","3g0fB-2psqA:44.35"],["3G0F_B_B49B9001_1","2r2p","Homo sapiens","EPHRIN TYPE-A RECEPTOR 5","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"VAL A 689;ALA A 705;THR A 753;TYR A 755;GLY A 759;LEU A 807","None","0.70A","3g0fB-2r2pA:31.2","3g0fB-2r2pA:32.35"],["3G0F_B_B49B9001_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"LEU A 724;VAL A 732;ALA A 749;THR A 796;GLY A 802;LEU A 850","GW7 A   1 ( 4.2A);GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-4.0A);GW7 A   1 (-3.6A);GW7 A   1 (-4.2A)","0.80A","3g0fB-2r4bA:28.0","3g0fB-2r4bA:30.70"],["3G0F_B_B49B9001_1","2wtk","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 11","PF00069(Pkinase)",6,"LEU C  55;VAL C  63;ALA C  76;TYR C 131;CYH C 132;LEU C 183","ANP C   2 ( 4.4A);ANP C   2 (-4.2A);ANP C   2 (-3.4A);None;ANP C   2 (-4.5A);None","0.60A","3g0fB-2wtkC:21.8","3g0fB-2wtkC:24.16"],["3G0F_B_B49B9001_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",6,"VAL A 635;ALA A 651;THR A 699;TYR A 701;GLY A 705;LEU A 753","Q9G A1898 ( 4.7A);Q9G A1898 (-3.2A);Q9G A1898 (-3.5A);Q9G A1898 (-4.8A);Q9G A1898 ( 3.8A);Q9G A1898 (-4.3A)","0.75A","3g0fB-2xyuA:31.6","3g0fB-2xyuA:31.88"],["3G0F_B_B49B9001_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"LEU A 487;VAL A 495;ALA A 515;TYR A 566;GLY A 570;LEU A 633","M33 A1996 (-4.0A);M33 A1996 ( 4.7A);M33 A1996 (-3.3A);M33 A1996 ( 4.7A);M33 A1996 ( 4.8A);M33 A1996 (-4.5A)","0.34A","3g0fB-3b2tA:33.1","3g0fB-3b2tA:47.42"],["3G0F_B_B49B9001_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"LEU A 484;VAL A 492;ALA A 512;TYR A 563;GLY A 567;LEU A 630;PHE A 489","C4F A   1 ( 3.9A);None;C4F A   1 (-3.3A);None;None;C4F A   1 (-4.6A);C4F A   1 (-3.7A)","0.75A","3g0fB-3c4fA:32.8","3g0fB-3c4fA:46.95"],["3G0F_B_B49B9001_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"VAL A 209;ALA A 220;THR A 266;TYR A 268;GLY A 272;LEU A 321","None","0.61A","3g0fB-3d7uA:30.8","3g0fB-3d7uA:32.34"],["3G0F_B_B49B9001_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 833;VAL A 841;ALA A 859;CYH A 912;GLY A 915;LEU A1029;CYH A1039;PHE A1041","8ST A2001 ( 4.7A);8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 (-3.8A);None;None;8ST A2001 (-4.2A);8ST A2001 ( 3.7A)","0.73A","3g0fB-3hngA:40.0","3g0fB-3hngA:45.95"],["3G0F_B_B49B9001_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 833;VAL A 841;ALA A 859;TYR A 911;CYH A 912;GLY A 915;LEU A1029;CYH A1039","8ST A2001 ( 4.7A);8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 (-4.9A);8ST A2001 (-3.8A);None;None;8ST A2001 (-4.2A)","0.58A","3g0fB-3hngA:40.0","3g0fB-3hngA:45.95"],["3G0F_B_B49B9001_1","3kex","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","PF07714(Pkinase_Tyr)",6,"LEU A 696;VAL A 704;THR A 768;TYR A 770;GLY A 774;LEU A 822","ANP A   1 (-4.4A);ANP A   1 (-3.9A);ANP A   1 ( 4.8A);ANP A   1 (-4.3A);ANP A   1 ( 4.9A);ANP A   1 (-4.7A)","0.63A","3g0fB-3kexA:26.7","3g0fB-3kexA:28.31"],["3G0F_B_B49B9001_1","3lm5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 17B","PF00069(Pkinase)",6,"LEU A  39;VAL A  47;ALA A  60;TYR A 112;GLY A 116;LEU A 165","QUE A   1 ( 3.8A);QUE A   1 ( 4.6A);QUE A   1 (-3.2A);QUE A   1 (-4.9A);None;None","0.47A","3g0fB-3lm5A:23.5","3g0fB-3lm5A:24.12"],["3G0F_B_B49B9001_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",6,"VAL A 218;ALA A 229;THR A 279;TYR A 281;GLY A 285;LEU A 339","LDN A   1 ( 4.8A);LDN A   1 (-3.6A);LDN A   1 (-3.8A);LDN A   1 ( 4.8A);LDN A   1 (-3.3A);LDN A   1 (-4.5A)","0.53A","3g0fB-3mdyA:23.9","3g0fB-3mdyA:27.59"],["3G0F_B_B49B9001_1","3mvj","Homo sapiens","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase)",6,"LEU A  49;VAL A  57;ALA A  70;TYR A 122;GLY A 126;LEU A 173","XFE A 351 (-4.2A);XFE A 351 ( 4.5A);XFE A 351 (-3.2A);None;None;XFE A 351 (-4.6A)","0.37A","3g0fB-3mvjA:21.8","3g0fB-3mvjA:23.38"],["3G0F_B_B49B9001_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",6,"LEU A  88;VAL A  96;ALA A 109;TYR A 161;GLY A 165;LEU A 212","JOZ A 361 (-4.1A);JOZ A 361 ( 4.7A);JOZ A 361 (-3.4A);None;None;None","0.42A","3g0fB-3nuuA:23.3","3g0fB-3nuuA:24.36"],["3G0F_B_B49B9001_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",6,"LEU A 726;VAL A 734;ALA A 751;THR A 798;GLY A 804;LEU A 852","03Q A   1 (-3.8A);03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.1A);03Q A   1 ( 3.9A);03Q A   1 (-4.4A)","0.80A","3g0fB-3pp0A:28.6","3g0fB-3pp0A:29.09"],["3G0F_B_B49B9001_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",7,"VAL A 565;ALA A 576;THR A 625;TYR A 627;GLY A 631;LEU A 683;CYH A 693","STU A   1 (-4.9A);STU A   1 (-3.3A);STU A   1 (-4.1A);STU A   1 (-4.4A);STU A   1 (-3.2A);STU A   1 (-4.3A);STU A   1 (-3.5A)","0.69A","3g0fB-3ppzA:27.5","3g0fB-3ppzA:33.33"],["3G0F_B_B49B9001_1","3q5i","Plasmodium berghei","PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",6,"LEU A  63;VAL A  71;ALA A  84;THR A 144;GLY A 150;LEU A 197","ANP A1634 ( 4.3A);ANP A1634 (-4.1A);ANP A1634 (-3.6A);ANP A1634 (-4.6A);None;ANP A1634 (-4.4A)","0.41A","3g0fB-3q5iA:20.1","3g0fB-3q5iA:20.34"],["3G0F_B_B49B9001_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",7,"LEU A 423;VAL A 431;ALA A 443;THR A 489;TYR A 491;GLY A 495;LEU A 543","PP2 A   1 (-4.1A);PP2 A   1 (-4.5A);PP2 A   1 (-3.2A);PP2 A   1 (-3.3A);PP2 A   1 ( 4.9A);PP2 A   1 ( 4.2A);PP2 A   1 (-4.6A)","0.66A","3g0fB-3sxsA:29.9","3g0fB-3sxsA:34.82"],["3G0F_B_B49B9001_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"LEU A 484;VAL A 492;ALA A 512;TYR A 563;GLY A 567;LEU A 630","07J A   1 ( 4.3A);07J A   1 (-4.0A);07J A   1 (-3.5A);07J A   1 (-4.7A);07J A   1 (-3.7A);07J A   1 ( 4.4A)","0.40A","3g0fB-3tt0A:33.5","3g0fB-3tt0A:42.93"],["3G0F_B_B49B9001_1","3ulz","Arabidopsis thaliana","BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1","PF00069(Pkinase)",6,"LEU A 295;VAL A 303;ALA A 315;TYR A 365;GLY A 369;LEU A 423","None","0.80A","3g0fB-3ulzA:21.9","3g0fB-3ulzA:24.04"],["3G0F_B_B49B9001_1","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 544;VAL A 552;ALA A 570;TYR A 619;GLY A 623;LEU A 686","0F4 A 902 ( 4.2A);None;0F4 A 902 (-3.2A);0F4 A 902 (-4.2A);0F4 A 902 (-3.4A);0F4 A 902 (-4.5A)","0.54A","3g0fB-3v5qA:32.7","3g0fB-3v5qA:34.42"],["3G0F_B_B49B9001_1","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 840;VAL A 848;ALA A 866;CYH A 919;GLY A 922;LEU A1035;CYH A1045","4TT A2001 ( 4.0A);4TT A2001 ( 4.5A);4TT A2001 (-3.5A);4TT A2001 (-4.3A);4TT A2001 (-3.7A);4TT A2001 (-4.8A);None","0.63A","3g0fB-3vidA:34.9","3g0fB-3vidA:46.58"],["3G0F_B_B49B9001_1","3w18","Homo sapiens","AURORA KINASE A","PF00069(Pkinase)",6,"LEU A 139;VAL A 147;ALA A 160;TYR A 212;GLY A 216;LEU A 263","N13 A 501 (-3.7A);N13 A 501 ( 4.7A);N13 A 501 ( 4.1A);N13 A 501 (-4.4A);N13 A 501 (-3.5A);N13 A 501 (-4.5A)","0.20A","3g0fB-3w18A:22.1","3g0fB-3w18A:24.78"],["3G0F_B_B49B9001_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 840;VAL A 848;ALA A 866;CYH A 919;GLY A 922;LEU A1035;CYH A1045","LEV A1201 ( 3.8A);LEV A1201 ( 4.9A);LEV A1201 (-3.5A);LEV A1201 (-4.1A);LEV A1201 (-3.6A);LEV A1201 (-4.8A);GOL A1210 ( 3.3A)","0.66A","3g0fB-3wzdA:34.2","3g0fB-3wzdA:52.13"],["3G0F_B_B49B9001_1","4af3","Homo sapiens","AURORA KINASE B","PF00069(Pkinase)",6,"LEU A  83;VAL A  91;ALA A 104;TYR A 156;GLY A 160;LEU A 207","VX6 A 500 (-3.8A);VX6 A 500 ( 4.8A);VX6 A 500 (-3.4A);VX6 A 500 (-4.2A);VX6 A 500 (-3.3A);VX6 A 500 (-4.6A)","0.44A","3g0fB-4af3A:19.7","3g0fB-4af3A:27.64"],["3G0F_B_B49B9001_1","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"LEU A 840;VAL A 848;ALA A 866;CYH A 919;GLY A 922;LEU A1035;CYH A1045;PHE A1047","B49 A2000 (-3.7A);None;B49 A2000 (-3.5A);B49 A2000 (-4.2A);B49 A2000 ( 3.7A);B49 A2000 (-4.5A);B49 A2000 ( 4.1A);B49 A2000 (-4.0A)","0.63A","3g0fB-4agdA:39.8","3g0fB-4agdA:50.00"],["3G0F_B_B49B9001_1","4agu","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 1","PF00069(Pkinase)",6,"VAL A  18;ALA A  31;TYR A  82;CYH A  83;LEU A 133;CYH A 143","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 (-4.8A);D15 A 500 (-4.3A);D15 A 500 (-4.5A);D15 A 500 ( 4.0A)","0.62A","3g0fB-4aguA:23.0","3g0fB-4aguA:24.93"],["3G0F_B_B49B9001_1","4at3","Homo sapiens","BDNF\/NT-3 GROWTH FACTORS RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 560;VAL A 568;ALA A 586;TYR A 635;GLY A 639;LEU A 699","LTI A1839 ( 4.2A);None;LTI A1839 (-3.3A);LTI A1839 (-4.7A);LTI A1839 (-3.4A);LTI A1839 (-4.2A)","0.64A","3g0fB-4at3A:31.5","3g0fB-4at3A:32.84"],["3G0F_B_B49B9001_1","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",6,"LEU A  42;VAL A  50;ALA A  63;CYH A 113;GLY A 116;LEU A 164","XZN A1317 (-3.6A);XZN A1317 ( 4.7A);XZN A1317 (-3.5A);XZN A1317 (-3.7A);XZN A1317 ( 3.7A);XZN A1317 (-4.7A)","0.75A","3g0fB-4bc6A:21.2","3g0fB-4bc6A:28.41"],["3G0F_B_B49B9001_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",6,"VAL A 222;ALA A 233;THR A 283;TYR A 285;GLY A 289;LEU A 343","TAK A1507 (-4.7A);TAK A1507 (-3.3A);TAK A1507 (-3.6A);TAK A1507 ( 4.6A);TAK A1507 (-3.5A);TAK A1507 (-4.7A)","0.82A","3g0fB-4c02A:24.7","3g0fB-4c02A:25.71"],["3G0F_B_B49B9001_1","4c0t","Candida albicans","LIKELY PROTEIN KINASE","PF00069(Pkinase)",6,"LEU A 246;VAL A 254;ALA A 267;TYR A 320;GLY A 324;LEU A 371","None","0.46A","3g0fB-4c0tA:22.9","3g0fB-4c0tA:16.05"],["3G0F_B_B49B9001_1","4cfh","Rattus norvegicus","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1","PF00069(Pkinase);PF16579(AdenylateSensor)",6,"LEU A  22;VAL A  30;ALA A  43;TYR A  95;GLY A  99;LEU A 146","STU A1550 (-4.3A);None;STU A1550 (-3.1A);STU A1550 (-4.5A);STU A1550 (-3.4A);STU A1550 (-4.3A)","0.55A","3g0fB-4cfhA:22.9","3g0fB-4cfhA:20.37"],["3G0F_B_B49B9001_1","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"ALA A 653;THR A 701;TYR A 703;GLY A 707;LEU A 773;PHE A 785","DI1 A1000 (-3.6A);DI1 A1000 (-3.6A);DI1 A1000 (-4.0A);None;DI1 A1000 (-4.5A);DI1 A1000 (-4.5A)","0.81A","3g0fB-4ckrA:32.8","3g0fB-4ckrA:31.01"],["3G0F_B_B49B9001_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 663;VAL A 671;ALA A 684;TYR A 739;GLY A 743;LEU A 789","AGS A1985 (-4.2A);AGS A1985 (-4.6A);AGS A1985 (-3.5A);None;None;AGS A1985 (-4.8A)","0.38A","3g0fB-4crsA:14.0","3g0fB-4crsA:22.33"],["3G0F_B_B49B9001_1","4f0i","Homo sapiens","HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 515;VAL A 523;ALA A 541;TYR A 590;GLY A 594;LEU A 656","None","0.74A","3g0fB-4f0iA:32.6","3g0fB-4f0iA:35.36"],["3G0F_B_B49B9001_1","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"LEU A 855;VAL A 863;ALA A 880;TYR A 931;GLY A 935;LEU A 983","IZA A2001 (-3.7A);None;IZA A2001 (-3.4A);None;IZA A2001 (-3.3A);IZA A2001 ( 4.7A)","0.68A","3g0fB-4gl9A:28.1","3g0fB-4gl9A:32.77"],["3G0F_B_B49B9001_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",6,"LEU A 828;VAL A 836;ALA A 853;TYR A 904;GLY A 908;LEU A 956","19S A1201 (-3.9A);19S A1201 (-4.4A);19S A1201 (-3.3A);19S A1201 (-4.7A);19S A1201 ( 3.8A);19S A1201 (-4.5A)","0.39A","3g0fB-4hviA:29.3","3g0fB-4hviA:31.30"],["3G0F_B_B49B9001_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",6,"LEU A 132;VAL A 140;ALA A 156;THR A 205;GLY A 211;LEU A 259","None","0.57A","3g0fB-4hzsA:27.1","3g0fB-4hzsA:32.86"],["3G0F_B_B49B9001_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",6,"LEU A 132;VAL A 140;ALA A 156;THR A 205;GLY A 211;LEU A 259","1G0 A 401 ( 4.5A);1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 (-3.2A);1G0 A 401 ( 4.5A);1G0 A 401 (-4.6A)","0.56A","3g0fB-4id7A:13.4","3g0fB-4id7A:34.04"],["3G0F_B_B49B9001_1","4jxf","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PLK4","PF00069(Pkinase)",6,"LEU A  18;VAL A  26;ALA A  39;CYH A  92;GLY A  95;LEU A 143","631 A 301 (-3.4A);631 A 301 (-4.6A);631 A 301 (-3.3A);631 A 301 (-4.5A);631 A 301 ( 3.7A);631 A 301 (-4.0A)","0.42A","3g0fB-4jxfA:18.4","3g0fB-4jxfA:25.14"],["3G0F_B_B49B9001_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 273;VAL A 281;ALA A 293;TYR A 340;GLY A 344;LEU A 393","0J9 A 601 (-4.0A);0J9 A 601 (-4.4A);0J9 A 601 (-3.3A);0J9 A 601 ( 4.7A);0J9 A 601 ( 4.1A);0J9 A 601 (-4.5A)","0.71A","3g0fB-4k11A:28.1","3g0fB-4k11A:26.06"],["3G0F_B_B49B9001_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",6,"LEU A 478;VAL A 486;ALA A 506;TYR A 557;GLY A 561;LEU A 624","ACP A 801 (-3.8A);ACP A 801 (-4.2A);ACP A 801 (-3.3A);None;ACP A 801 ( 4.6A);ACP A 801 (-4.4A)","0.62A","3g0fB-4k33A:27.3","3g0fB-4k33A:47.81"],["3G0F_B_B49B9001_1","4l52","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7, TGF-BETA-ACTIVATED KINASE 1 AND MAP3K7-BINDING PROTEIN 1 CHIMERA","PF07714(Pkinase_Tyr)",6,"VAL A  50;ALA A  61;TYR A 106;GLY A 110;LEU A 163;CYH A 174","1UL A 501 ( 4.9A);1UL A 501 (-3.1A);1UL A 501 (-4.1A);1UL A 501 ( 3.7A);1UL A 501 (-4.3A);1UL A 501 (-3.6A)","0.66A","3g0fB-4l52A:25.2","3g0fB-4l52A:28.95"],["3G0F_B_B49B9001_1","4lg4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"LEU A  33;VAL A  41;ALA A  54;TYR A 101;CYH A 102;GLY A 105","GOL A 404 ( 3.6A);GOL A 404 (-4.5A);GOL A 404 ( 3.1A);GOL A 404 ( 4.9A);GOL A 403 (-4.0A);GOL A 404 (-3.6A)","0.51A","3g0fB-4lg4A:23.5","3g0fB-4lg4A:26.01"],["3G0F_B_B49B9001_1","4lg4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"VAL A  41;ALA A  54;TYR A 101;CYH A 102;GLY A 105;LEU A 153","GOL A 404 (-4.5A);GOL A 404 ( 3.1A);GOL A 404 ( 4.9A);GOL A 403 (-4.0A);GOL A 404 (-3.6A);GOL A 403 ( 4.4A)","0.66A","3g0fB-4lg4A:23.5","3g0fB-4lg4A:26.01"],["3G0F_B_B49B9001_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",6,"LEU A 273;VAL A 281;ALA A 293;TYR A 340;GLY A 344;LEU A 393","VGG A 601 (-3.2A);VGG A 601 ( 3.5A);VGG A 601 (-3.5A);VGG A 601 ( 4.0A);VGG A 601 ( 3.2A);VGG A 601 (-4.5A)","0.75A","3g0fB-4lggA:27.6","3g0fB-4lggA:35.57"],["3G0F_B_B49B9001_1","4mvf","Plasmodium falciparum","CALCIUM-DEPENDENT PROTEIN KINASE 2","PF00069(Pkinase);PF13499(EF-hand_7)",6,"LEU A  78;VAL A  86;ALA A  99;CYH A 149;GLY A 151;LEU A 199","STU A 601 ( 4.0A);STU A 601 (-4.8A);STU A 601 (-3.3A);STU A 601 (-4.2A);STU A 601 (-3.4A);STU A 601 (-4.7A)","0.53A","3g0fB-4mvfA:18.9","3g0fB-4mvfA:21.33"],["3G0F_B_B49B9001_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",8,"LEU A  46;VAL A  54;ALA A  67;THR A 123;CYH A 126;GLY A 128;LEU A 180;CYH A 190","SIN A 401 ( 3.9A);None;SIN A 401 ( 3.7A);None;SIN A 401 (-4.3A);SIN A 401 (-3.5A);SIN A 401 ( 4.5A);None","0.61A","3g0fB-4o38A:20.2","3g0fB-4o38A:24.93"],["3G0F_B_B49B9001_1","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"LEU A 595;VAL A 603;THR A 687;TYR A 689;GLY A 693;LEU A 741","2TT A1201 (-4.1A);2TT A1201 (-4.2A);None;2TT A1201 (-4.0A);2TT A1201 (-3.5A);2TT A1201 (-4.1A)","0.82A","3g0fB-4oliA:27.0","3g0fB-4oliA:22.34"],["3G0F_B_B49B9001_1","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"LEU A 903;VAL A 911;ALA A 928;TYR A 980;GLY A 984;LEU A1030","2TT A1202 (-3.5A);2TT A1202 (-4.5A);2TT A1202 ( 3.9A);2TT A1202 (-4.6A);2TT A1202 (-3.4A);2TT A1202 (-4.4A)","0.48A","3g0fB-4oliA:27.0","3g0fB-4oliA:22.34"],["3G0F_B_B49B9001_1","4otd","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N1","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 627;VAL A 635;ALA A 648;TYR A 703;GLY A 707;LEU A 753","None","0.32A","3g0fB-4otdA:22.2","3g0fB-4otdA:23.59"],["3G0F_B_B49B9001_1","4p2k","Homo sapiens","EPHRIN TYPE-A RECEPTOR 2","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"VAL A 627;ALA A 644;THR A 692;TYR A 694;GLY A 698;LEU A 746","None","0.81A","3g0fB-4p2kA:30.6","3g0fB-4p2kA:32.45"],["3G0F_B_B49B9001_1","4q9z","Homo sapiens","HUMAN PROTEIN KINASE C THETA","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 386;VAL A 394;ALA A 407;TYR A 460;GLY A 464;LEU A 511","PZW A 801 (-3.9A);PZW A 801 (-4.6A);PZW A 801 (-3.5A);None;None;PZW A 801 (-4.8A)","0.69A","3g0fB-4q9zA:20.5","3g0fB-4q9zA:24.24"],["3G0F_B_B49B9001_1","4rew","Homo sapiens","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1","PF00069(Pkinase);PF16579(AdenylateSensor)",6,"LEU A  24;VAL A  32;ALA A  45;TYR A  97;GLY A 101;LEU A 148","STU A 601 (-3.7A);STU A 601 ( 4.8A);STU A 601 (-3.2A);STU A 601 (-4.4A);STU A 601 ( 3.8A);STU A 601 (-4.2A)","0.54A","3g0fB-4rewA:22.4","3g0fB-4rewA:19.78"],["3G0F_B_B49B9001_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",9,"LEU A 616;VAL A 624;ALA A 642;TYR A 693;CYH A 694;GLY A 697;LEU A 818;CYH A 828;PHE A 830","P30 A1001 (-3.8A);None;P30 A1001 (-3.4A);P30 A1001 (-4.1A);None;P30 A1001 (-3.4A);P30 A1001 (-4.6A);P30 A1001 (-4.1A);P30 A1001 (-3.9A)","0.61A","3g0fB-4rt7A:40.7","3g0fB-4rt7A:48.43"],["3G0F_B_B49B9001_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",7,"LEU A  14;VAL A  22;ALA A  35;THR A  81;TYR A  83;GLY A  87;LEU A 136","ACP A1264 ( 4.5A);ACP A1264 (-4.7A);ACP A1264 (-2.9A);ACP A1264 (-4.5A);ACP A1264 ( 4.5A);ACP A1264 (-3.5A);ACP A1264 ( 4.8A)","0.67A","3g0fB-4ueuA:31.0","3g0fB-4ueuA:35.88"],["3G0F_B_B49B9001_1","4wb7","Homo sapiens","DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase);PF00226(DnaJ)",6,"LEU A 104;VAL A 112;ALA A 125;TYR A 177;GLY A 181;LEU A 228","ATP A 501 ( 4.3A);ATP A 501 (-4.0A);ATP A 501 (-3.4A);None;None;ATP A 501 (-4.5A)","0.39A","3g0fB-4wb7A:21.5","3g0fB-4wb7A:23.73"],["3G0F_B_B49B9001_1","4wov","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"LEU A 595;VAL A 603;THR A 687;TYR A 689;GLY A 693;LEU A 741","3SM A 901 (-3.9A);3SM A 901 ( 4.4A);3SM A 901 ( 4.6A);3SM A 901 (-3.2A);3SM A 901 (-3.0A);3SM A 901 (-4.1A)","0.69A","3g0fB-4wovA:22.5","3g0fB-4wovA:25.83"],["3G0F_B_B49B9001_1","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"LEU A  52;VAL A  60;ALA A  72;CYH A 129;GLY A 132;LEU A 183;CYH A 193","KSA A 405 ( 4.0A);KSA A 405 ( 4.9A);KSA A 405 (-3.2A);KSA A 405 (-4.5A);KSA A 405 (-3.5A);KSA A 405 (-4.6A);KSA A 405 (-3.4A)","0.54A","3g0fB-4wsqA:22.6","3g0fB-4wsqA:22.16"],["3G0F_B_B49B9001_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",6,"LEU B 267;VAL B 275;ALA B 288;THR B 334;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.71A","3g0fB-4xeyB:30.6","3g0fB-4xeyB:30.19"],["3G0F_B_B49B9001_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 408;VAL A 416;ALA A 428;THR A 474;TYR A 476;LEU A 528","None","0.77A","3g0fB-4xi2A:28.6","3g0fB-4xi2A:26.04"],["3G0F_B_B49B9001_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",9,"LEU A 616;VAL A 624;ALA A 642;TYR A 693;CYH A 694;GLY A 697;LEU A 818;CYH A 828;PHE A 830","P30 A1001 (-4.0A);P30 A1001 ( 4.8A);P30 A1001 (-3.5A);P30 A1001 ( 4.4A);P30 A1001 (-4.2A);P30 A1001 (-3.5A);P30 A1001 (-4.3A);P30 A1001 (-4.8A);P30 A1001 ( 4.1A)","0.70A","3g0fB-4xufA:39.9","3g0fB-4xufA:60.20"],["3G0F_B_B49B9001_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",7,"LEU A 408;VAL A 416;ALA A 428;THR A 474;TYR A 476;GLY A 480;LEU A 528","746 A 702 (-3.8A);746 A 702 ( 4.3A);746 A 702 (-2.4A);746 A 702 (-3.7A);746 A 702 (-4.4A);746 A 702 (-3.6A);746 A 702 (-4.4A)","0.54A","3g0fB-4y93A:29.7","3g0fB-4y93A:26.37"],["3G0F_B_B49B9001_1","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",6,"VAL A 477;ALA A 488;THR A 539;TYR A 541;GLY A 545;LEU A 595","None;4CV A 801 (-3.5A);4CV A 801 (-2.8A);4CV A 801 (-3.9A);4CV A 801 ( 4.0A);4CV A 801 (-4.4A)","0.56A","3g0fB-4yffA:24.8","3g0fB-4yffA:28.07"],["3G0F_B_B49B9001_1","4ysj","Eimeria tenella","CALMODULIN-LIKE DOMAIN PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",6,"LEU A  34;VAL A  42;ALA A  55;THR A 105;GLY A 111;LEU A 158","ADP A 506 ( 3.8A);ADP A 506 (-4.3A);ADP A 506 (-3.3A);ADP A 506 ( 4.6A);None;ADP A 506 (-4.7A)","0.44A","3g0fB-4ysjA:22.5","3g0fB-4ysjA:19.85"],["3G0F_B_B49B9001_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",6,"LEU A 484;VAL A 492;ALA A 512;TYR A 563;GLY A 567;LEU A 630","38O A1769 (-3.2A);38O A1769 (-4.5A);38O A1769 (-3.6A);38O A1769 (-4.2A);38O A1769 (-3.4A);38O A1769 (-4.6A)","0.29A","3g0fB-5a46A:33.8","3g0fB-5a46A:41.97"],["3G0F_B_B49B9001_1","5ci7","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE ULK1","PF00069(Pkinase)",6,"VAL A  30;ALA A  44;TYR A  94;CYH A  95;GLY A  98;LEU A 145","51W A 401 ( 4.3A);51W A 401 (-3.4A);51W A 401 ( 3.4A);51W A 401 (-3.9A);51W A 401 (-3.7A);51W A 401 (-4.5A)","0.28A","3g0fB-5ci7A:23.4","3g0fB-5ci7A:29.49"],["3G0F_B_B49B9001_1","5e8y","Homo sapiens","TGF-BETA RECEPTOR TYPE-2","PF07714(Pkinase_Tyr)",6,"VAL A 258;ALA A 275;THR A 325;GLY A 331;LEU A 386;CYH A 396","STU A 601 (-4.0A);STU A 601 (-3.1A);STU A 601 ( 3.7A);STU A 601 (-3.5A);STU A 601 (-3.9A);STU A 601 (-3.2A)","0.61A","3g0fB-5e8yA:24.2","3g0fB-5e8yA:27.15"],["3G0F_B_B49B9001_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"LEU A 903;VAL A 911;ALA A 928;TYR A 980;GLY A 984;LEU A1030","5U3 A1200 (-3.8A);5U3 A1200 ( 4.4A);5U3 A1200 (-3.5A);5U3 A1200 (-4.5A);5U3 A1200 (-3.2A);5U3 A1200 (-4.4A)","0.37A","3g0fB-5f1zA:22.2","3g0fB-5f1zA:32.85"],["3G0F_B_B49B9001_1","5fm2","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","PF07714(Pkinase_Tyr)",6,"LEU A 730;VAL A 738;ALA A 756;TYR A 806;GLY A 810;LEU A 881","PP1 A2012 (-4.6A);PP1 A2012 (-4.4A);PP1 A2012 (-3.2A);None;PTR A 809 (-2.4A);PP1 A2012 (-4.6A)","0.66A","3g0fB-5fm2A:32.0","3g0fB-5fm2A:42.46"],["3G0F_B_B49B9001_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",10,"LEU A 599;VAL A 607;ALA A 625;THR A 674;TYR A 676;CYH A 677;GLY A 680;LEU A 825;CYH A 835;PHE A 837","748 A1001 (-3.8A);748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-3.2A);748 A1001 (-4.0A);748 A1001 (-4.5A);748 A1001 ( 4.0A);748 A1001 (-4.3A);748 A1001 (-4.5A);748 A1001 (-3.7A)","0.61A","3g0fB-5grnA:30.8","3g0fB-5grnA:60.00"],["3G0F_B_B49B9001_1","5gz8","Mus musculus","PROTEIN O-MANNOSE KINASE","PF07714(Pkinase_Tyr)",6,"VAL A  94;ALA A 105;THR A 148;TYR A 150;GLY A 154;LEU A 215","None","0.62A","3g0fB-5gz8A:18.4","3g0fB-5gz8A:22.91"],["3G0F_B_B49B9001_1","5gza","Danio rerio","PROTEIN O-MANNOSE KINASE","PF07714(Pkinase_Tyr)",6,"VAL A  93;ALA A 104;THR A 147;TYR A 149;GLY A 153;LEU A 214","ADP A 401 (-4.4A);ADP A 401 (-3.2A);ADP A 401 ( 4.8A);ADP A 401 ( 4.8A);ADP A 401 ( 4.1A);ADP A 401 (-4.4A)","0.65A","3g0fB-5gzaA:18.2","3g0fB-5gzaA:23.73"],["3G0F_B_B49B9001_1","5hes","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLT","PF07714(Pkinase_Tyr)",6,"VAL A  30;ALA A  43;THR A  82;TYR A  84;GLY A  88;CYH A 150","032 A 401 (-4.4A);032 A 401 (-3.2A);032 A 401 (-3.7A);032 A 401 (-4.2A);032 A 401 ( 4.0A);032 A 401 (-3.6A)","0.78A","3g0fB-5hesA:24.6","3g0fB-5hesA:26.79"],["3G0F_B_B49B9001_1","5i3o","Homo sapiens","BMP-2-INDUCIBLE PROTEIN KINASE","PF00069(Pkinase)",8,"LEU A  57;VAL A  65;ALA A  77;TYR A 132;CYH A 133;GLY A 136;LEU A 187;CYH A 197","IDV A 401 (-3.8A);IDV A 401 (-4.6A);IDV A 401 (-3.6A);IDV A 401 (-3.5A);IDV A 401 (-4.6A);IDV A 401 (-3.4A);IDV A 401 (-4.4A);IDV A 401 (-3.6A)","0.69A","3g0fB-5i3oA:22.4","3g0fB-5i3oA:25.07"],["3G0F_B_B49B9001_1","5iso","Homo sapiens","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2","PF00069(Pkinase);PF16579(AdenylateSensor)",6,"LEU A  22;VAL A  30;ALA A  43;TYR A  95;GLY A  99;LEU A 146","STU A 601 (-4.1A);STU A 601 (-4.8A);STU A 601 (-3.3A);STU A 601 (-4.3A);STU A 601 ( 4.0A);STU A 601 (-4.5A)","0.40A","3g0fB-5isoA:22.8","3g0fB-5isoA:19.70"],["3G0F_B_B49B9001_1","5o0y","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TOUSLED-LIKE 2","no annotation",6,"LEU A 468;VAL A 476;ALA A 489;TYR A 546;CYH A 547;GLY A 549","AGS A 801 (-4.1A);AGS A 801 (-4.0A);AGS A 801 (-3.6A);AGS A 801 ( 4.8A);AGS A 801 (-4.3A);None","0.66A","3g0fB-5o0yA:21.2","3g0fB-5o0yA:12.27"],["3G0F_B_B49B9001_1","5tvt","Homo sapiens","MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE","no annotation",6,"VAL A  25;ALA A  38;TYR A  88;CYH A  89;GLY A  92;LEU A 139","7LV A 401 ( 4.6A);7LV A 401 (-3.4A);7LV A 401 (-4.6A);7LV A 401 (-4.3A);None;7LV A 401 (-4.9A)","0.43A","3g0fB-5tvtA:22.4","3g0fB-5tvtA:23.50"],["3G0F_B_B49B9001_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",7,"LEU A  24;VAL A  32;ALA A  45;THR A  95;TYR A  97;GLY A 101;LEU A 153","9WS A 401 ( 4.2A);9WS A 401 ( 4.6A);9WS A 401 (-3.3A);9WS A 401 (-3.2A);None;9WS A 401 ( 4.3A);9WS A 401 (-4.6A)","0.54A","3g0fB-5w5jA:8.9","3g0fB-5w5jA:28.21"],["3G0F_B_B49B9001_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",7,"LEU A 891;VAL A 899;ALA A 917;THR A 963;TYR A 965;GLY A 969;LEU A1017","ANP A1201 (-4.1A);ANP A1201 (-4.4A);ANP A1201 (-3.3A);ANP A1201 (-3.9A);ANP A1201 (-4.4A);ANP A1201 ( 4.6A);ANP A1201 (-4.7A)","0.71A","3g0fB-5wnoA:26.0","3g0fB-5wnoA:11.90"],["3G0F_B_B49B9001_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",7,"LEU A  33;VAL A  41;ALA A  54;TYR A 101;CYH A 102;GLY A 105;LEU A 153","ANP A 501 ( 3.8A);ANP A 501 (-4.4A);ANP A 501 ( 3.7A);ANP A 501 ( 4.2A);ANP A 501 (-4.2A);ANP A 501 ( 4.0A);ANP A 501 (-4.6A)","0.64A","3g0fB-6ao5A:21.5","3g0fB-6ao5A:23.40"],["3G0F_B_B49B9001_1","6fdy","-","-","no annotation",6,"LEU U  20;VAL U  28;ALA U  42;CYH U  94;GLY U  97;LEU U 144","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 (-4.2A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A)","0.73A","3g0fB-6fdyU:21.9","3g0fB-6fdyU:undetectable"],["3G0F_B_B49B9001_1","6fek","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","no annotation",6,"LEU A 730;VAL A 738;ALA A 756;TYR A 806;GLY A 810;LEU A 881","ADN A1104 ( 4.0A);ADN A1104 (-4.4A);ADN A1104 (-3.4A);ADN A1104 ( 4.1A);ADN A1104 ( 3.8A);ADN A1104 (-4.3A)","0.58A","3g0fB-6fekA:31.8","3g0fB-6fekA:19.23"]]